| abstract |
The present invention provides nucleic acid constructs, pharmaceutical compositions and methods that can be used to control angiogenesis in specific cell regions. A modified preproendothelin-1 (PPE-1) promoter exhibiting increased activity and specificity in endothelial cells and activation of cytotoxicity of specific cell subsets, characterized by neovascularization or cell proliferation. A nucleic acid construct capable of treating a certain disease or an ischemic disease by inducing the growth of new blood vessels. Furthermore, a modification of the PPE promoter that increases the expression of the PPE promoter in response to physiological conditions such as hypoxia and angiogenesis, and a novel angiogenic endothelium-specific combination therapy. [Selection figure] None |